Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
|Articles|December 1, 2015
Supply Chain Pains Turn to Gains
December 01, 2015.
Advertisement
UPS has announced the results of its 2015 Pain in the (Supply) Chain survey of global healthcare executives on their top supply chain and business issues, strategies and opportunities. Among the findings:
- Healthcare companies have made significant strides in just one year to address some top supply chain pain points:
- 75% of respondents report success addressing product security vs. 55% in 2014
- 70% of respondents report success in addressing regulatory compliance vs. 57% in 2014
- Issues remain in the healthcare supply chain:
- Only 50% of respondents report success addressing supply chain cost management; the top challenge to managing costs is rapid business growth, cited by 56%
- Physical protection from theft (46%) and poor supply chain visibility and too many supply chain hand-offs (40%) are the biggest product security challenges
- Contingency planning is not prioritized by healthcare executives
- Partnerships are the top successful strategy healthcare companies are using to address regulatory compliance, product damage and spoilage and cost management.
For further information, visit the
Advertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
The top barrier to AI adoption among pharma commercial leaders is compliance uncertainty, and the fix may be governance that evaluates one use case at a time.
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
ANI Pharmaceuticals to Acquire Egetis Therapeutics, Egetis Sells Priority Review Voucher for $190 Million
2
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
3
Pharmaceutical Executive Daily: Nxera Licenses EP4 Agonist to AbbVie
4
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
5